Innoviva, Inc. Common Stock (INVA)

Price$21.51

Value ScoreB

Growth ScoreC

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-14.70%

Price vs S&P 500 (4W)-12.28%

VGM Score58.73

Market Capitalization$1.58B

P/E Ratio (Annual)5.83x

All Metrics

P/CF (Annual)8.03x

Book Value / Share (Quarterly)$18.18

P/TBV (Annual)1.60x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)7.48%

Cash Flow / Share (Quarterly)$2.34

Price vs S&P 500 (YTD)-3.78%

Gross Margin (TTM)73.73%

Net Profit Margin (TTM)119.88%

EPS (TTM)$5.94

10-Day Avg Trading Volume0.97M

EPS Excl Extra (TTM)$5.94

Revenue Growth (5Y)4.08%

EPS (Annual)$3.20

ROI (Annual)18.96%

Gross Margin (Annual)74.80%

Net Profit Margin (5Y Avg)52.55%

Cash / Share (Quarterly)$8.29

P/E Basic Excl Extra (TTM)3.13x

Revenue Growth QoQ (YoY)10.56%

EPS Growth (5Y)10.12%

P/E Normalized (Annual)5.83x

ROA (Last FY)16.58%

Revenue Growth TTM (YoY)13.75%

EBITD / Share (TTM)$2.05

ROE (5Y Avg)31.01%

Operating Margin (TTM)38.14%

Cash Flow / Share (Annual)$2.50

P/B Ratio1.18x

P/B Ratio (Quarterly)1.29x

Net Income / Employee (Annual)$1,705,400

EV / Revenue (TTM)2.94x

Net Interest Coverage (TTM)1.30x

ROA (TTM)32.36%

EPS Growth QoQ (YoY)919.12%

EV / EBITDA (TTM)7.09x

EPS Incl Extra (Annual)$3.20

Current Ratio (Annual)14.64x

Quick Ratio (Quarterly)19.39x

3-Month Avg Trading Volume0.75M

52-Week Price Return9.90%

EV / Free Cash Flow (Annual)6.63x

P/E Incl Extra (TTM)3.13x

Revenue / Employee (TTM)$2,645,800

Tangible BV / Share (Quarterly)$15.08

P/S Ratio (Annual)3.84x

Asset Turnover (Annual)0.25x

52-Week High$25.15

Operating Margin (5Y Avg)71.09%

EPS Excl Extra (Annual)$3.20

Tangible BV CAGR (5Y)17.65%

26-Week Price Return1.23%

Quick Ratio (Annual)13.31x

13-Week Price Return-9.01%

Total Debt / Equity (Annual)0.22x

Current Ratio (Quarterly)21.13x

Enterprise Value$1.24B

Revenue / Share Growth (5Y)10.36%

Asset Turnover (TTM)0.27x

Book Value / Share Growth (5Y)24.17%

Revenue / Employee (Annual)$2,587,000

Inventory Turnover (Annual)2.84x

Pretax Margin (Annual)79.47%

Cash / Share (Annual)$7.59

3-Month Return Std Dev23.81%

Net Income / Employee (TTM)$3,172,000

EBITDA CAGR (5Y)-11.90%

EBITDA Interim CAGR (5Y)-12.89%

ROE (Last FY)23.12%

Net Interest Coverage (Annual)0.80x

EPS Basic Excl Extra (Annual)$3.20

P/FCF (TTM)9.16x

Receivables Turnover (TTM)4.93x

EV / Free Cash Flow (TTM)7.16x

Total Debt / Equity (Quarterly)0.19x

EPS Incl Extra (TTM)$5.94

Receivables Turnover (Annual)4.58x

ROI (TTM)36.94%

P/S Ratio (TTM)3.76x

Pretax Margin (5Y Avg)70.53%

Revenue / Share (Annual)$4.85

Tangible BV / Share (Annual)$12.52

Forward P/E7.60x

Free OCF CAGR (5Y)-9.85%

Price vs S&P 500 (52W)-18.30%

P/E Ratio (TTM)3.13x

EPS Growth TTM (YoY)3397.08%

Year-to-Date Return7.15%

5-Day Price Return-4.63%

EPS Normalized (Annual)$3.20

ROA (5Y Avg)15.78%

Net Profit Margin (Annual)65.92%

Month-to-Date Return-6.83%

Cash Flow / Share (TTM)$1.03

EBITD / Share (Annual)$2.10

EPS Growth (3Y)12.50%

Operating Margin (Annual)39.81%

LT Debt / Equity (Annual)0.22x

P/CF (TTM)8.61x

ROI (5Y Avg)17.85%

P/E Excl Extra (TTM)3.13x

LT Debt / Equity (Quarterly)0.19x

EPS Basic Excl Extra (TTM)$5.94

P/TBV (Quarterly)1.55x

P/B Ratio (Annual)1.27x

Inventory Turnover (TTM)2.75x

Pretax Margin (TTM)142.63%

Book Value / Share (Annual)$15.71

Price vs S&P 500 (13W)-18.75%

Net Margin Growth (5Y)-0.21%

Beta0.36x

P/FCF (Annual)8.48x

Revenue / Share (TTM)$4.96

ROE (TTM)47.59%

52-Week Low$16.52

vGradeB

gGradeC

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.05est. 0.40

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.00

4.09

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
INVAInnoviva, Inc. Common Stock	B	C	C	$21.51
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Innoviva Inc generates revenue through a portfolio of pharmaceutical royalties and operating assets in critical care and infectious disease. Its holdings include branded respiratory therapies such as Trelegy, Anoro, and the Relvar/Breo/Ellipta franchise, which provide recurring revenue streams from established, marketed products.